Alterations in Plasma miR-21, miR-590, miR-192 and miR-215 in Patients with Idiopathic Pulmonary Fibrosis and Their Clinical Importance

Background: It is well-established that microRNAs (miRNAs) have regulatory roles in the brotic processes of various tissues. Studies revealed that some miRNAs play a pivotal role in the development of idiopathic pulmonary brosis (IPF). Methods: In this single-center, cross-sectional study, the plasma levels of miR-21, miR-590, miR-192, and miR-215 in IPF (n=88) and the control (n=20) group were investigated using real-time PCR. The pulmonary function tests and the plasma sampling of participants were carried out simultaneously. Patients were grouped according to age, forced vital capacity, diffusing capacity for carbon monoxide (DLCO), and the Gender-Age-pulmonary Physiology (GAP) score. The expression levels of the target miRNAs between these clinical subgroups were compared. Results: The IPF and control groups were similar in terms of gender and age. The mean plasma miR-21 and miR-590 levels in IPF were signicantly higher than in the control (p<0.0001, p<0.0001, respectively). There was no signicant difference in miR-192 and miR-215 levels between the groups. While miR-21 and miR-590 correlated positively with age (p=0.041, p=0.007, respectively), miR-192 and miR-215 displayed a negative correlation with age (p=0.0002, p<0.0001, respectively). MiR-192 and miR-215 increased as the GAP score decreased and miR-192 level in patients with honeycombing was signicantly lower than in those without honeycombing (p=0.003). Conclusions: Our results suggest that higher plasma levels of miR-21 and miR-590 were related to the presence of IPF. While all target miRNAs correlated with age, the miR-21 and miR-590 were associated with DLCO, and miR-192 and miR-215 were associated with GAP score and honeycombing.

Therefore, it is predicted that these two miRNA molecules could share target mRNA molecules and take part in similar cellular pathways. miR-21 has been shown to contribute to both pulmonary and cardiac brosis processes [9]. Although miR-590 has been reported to be associated with cardiac brosis, its role in pulmonary brosis has not been studied yet [10].
The miR-192 molecule has also been reported to be involved in the development of brosis. Extensive studies are being conducted on the regulatory role of miR-192 in brosis, particularly in renal brosis.
Furthermore, miR-192 was shown to be increased in bleomycin-induced brotic lungs of mice, and miR-192 was found in the sputum of patients with IPF [11,12]. However, there is no data about its relation with IPF severity. As between miR-21 and miR-590, there is a strong sequence homology between miR-192 and miR-215 molecules. Although miR-215 was reported to regulate broblast function, there is no data about its role in lung brosis [13].
Currently, the interest in the association between circulating extracellular miRNA and the development and prognosis of IPF has been increasing. Therefore, the plasma expression levels of miR-21, miR-590, miR-192, and miR-215 molecules in IPF and their relationship with the clinical features were investigated in this study.

Study Design and Participants
This single-center, cross-sectional study was conducted in the Chest Diseases Department of Akdeniz University Hospital between June 2018 and August 2020. IPF patients who are meeting the criteria of the 2018 American Thoracic Society / European Respiratory Society Clinical Practice Guidelines, and do not have heart disease, cancer, renal failure, or hepatic disease, were included in the IPF group [9]. The control group consisted of healthy subjects who matched the IPF group in terms of age and gender.

Clinical Features
The demographic data and clinical characteristics of the patients (age, gender, smoking history, symptoms, drug therapy, lung biopsy) were obtained. Recent high-resolution computer tomography (HRCT) images of subjects were used and subpleural, basal dominant reticulation with honeycombing was accepted as usual interstitial pneumonia (UIP) pattern. The severity of dyspnea was determined with a modi ed Medical Research Council (mMRC) Questionnaire. The gender-age-pulmonary physiology (GAP) score was calculated using gender, age, % of predicted forced vital capacity (FVC), and % of predicted diffusing capacity for carbon monoxide (DLCO). Spirometry and helium diffusion tests were applied to evaluate respiratory functions in the IPF group and simultaneously blood samples were taken for miRNA analysis. The data of age, gender, smoking history, and comorbidities were obtained from healthy control subjects. Blood samples were collected for miRNA analysis but spirometry and helium diffusion tests were not performed in the control group.

Human ethics
Written informed consent was obtained from all patients and control subjects. Approval for study was

Statistical Analysis
Statistical analysis of the data was performed using GraphPad Prizm 9 (GraphPad Software, USA) program. Descriptive statistics for categorical variables were reported as number (n) and percentage (%) and for continuous variables as mean ± standard deviation (SD) or mean ± standard error of mean (SEM) values. Differences of means between two independent groups were examined with the Mann-Whitney U test, and between more than two independent groups with Kruskal Wallis analysis. Relationships of two independent categorical variables were interpreted by Chi-Square analysis or with Fisher's Exact Test. The correlation of independent continuous variables was analyzed with Spearman's rank correlation test. In all analyses, a value of p≤0.05 was considered statistically signi cant.

Results
Demographic features, respiratory functions, and radiological ndings Eighty-eight patients with IPF and 20 healthy control subjects were evaluated in this study. IPF group comprised 82 (93.18%) males and the mean age was 66.6 ± 8.6 years [ Table 1]. There was no difference between IPF and control group in terms of gender, age, and smoking amount but the ratio of smokers was higher in IPF than in control group (71% vs. 45%, p = 0.038). Majority of the patients (81.8%) had dyspnea in various degrees and the median mMRC score was 2. The mean FVC (% of pred.) was 71.3 ± 17.1% and DLCO (% of pred.) was 60.6 ± 17.8%. Clinical features of IPF patients were different between younger and older groups [ Table 2]. Gender and smoking features in IPF were similar in both age-groups. UIP pattern was signi cantly more common (p = 0.015) and the GAP score was higher (p = 0.001) in the older group however, the mean FVC and DLCO values were similar. miRNA levels in IPF and control group The mean plasma miR-21 and miR-590 levels in IPF were at least two-fold higher than in control group [ Figure 1]. There was no signi cant difference in the mean plasma miR-192 and miR-215 levels between the groups. Also, plasma levels of target miRNA molecules weren't altered signi cantly with smoking in 1.44 ± 0.65, p > 0.05; anti-brotic therapy no vs. yes, respectively). A positive correlation was found between the levels of miR-21 and miR-590 and between the levels of miR-192 and miR-215 in both IPF and control groups [ Figure 2].
Association of miRNAs with pulmonary function tests, GAP score and radiological ndings in patients with IPF In FVC subgroups, no difference was determined in plasma levels of miR-590, miR-192, and miR-215 [Supplemental Table-1], but a slight difference was seen in miR-21 level. miR-21 level of patients with FVC > 80% was higher than that of patients with FVC 66-80% (1.6 ± 0.9 vs. 1.2 ± 0.9, p = 0.012).
In DLCO subgroups, there was no signi cant difference in miR-192 and miR-215 levels [Supplemental Table-1]. Both miR-21 and miR-590 were reduced in patients with DLCO < 45% compared to other DLCO subgroups, but the miR-21 and miR-590 levels of this group were similar to those of control subjects [ Figure 4]. Although plasma miR-21 and miR-590 levels weren't signi cantly changed among DLCO subgroups (with Kruskal Wallis test), patients with the highest DLCO levels showed signi cantly increased miR-590 levels compared to patients with the lowest DLCO values (1.5 ± 0.9 vs. 1.0 ± 1.1, p = 0.022 with Mann-Whitney U test).
miR-21 and miR-590 did not change according to GAP score [Supplemental Table-2]. In contrast, miR-192 and miR-215 were reduced along with the increased GAP scores [ Figure 5]. The plasma miR-192 level was signi cantly reduced in the patients whose GAP scores are higher than 2 (p = 0.010). Although the plasma miR-215 levels were not signi cantly changed with GAP score (p = 0.071), their levels were reduced in the patients with a GAP score higher than 2 (p < 0.05 with Mann Whitney U test).
Related to the radiological ndings, the mean plasma miR-215 levels were lower in patients with honeycombing compared to those without honeycombing, but the difference was not signi cant [Supplemental Table-2]. The mean plasma miR-192 level in patients with honeycombing was signi cantly lower than in those without honeycombing (p = 0.003) [ Figure 6].

Discussion
In this study, we investigated plasma miR-21, miR-590, miR-192, and miR-215 levels in IPF patients. The plasma miR-21 and miR-590 levels in IPF group were signi cantly higher than those of the control group, but there was no signi cant difference in miR-192 and miR-215 levels. Moreover, miR-21 and miR-590 were associated with age and DLCO, while miR-192 and miR-215 were associated with age, GAP score, and honeycombing. These ndings suggested that miR-21 and miR-590 could take a role in the development of IPF, additionally, miR-192 and miR-215 also could be related to the progression of the IPF.
MiRNA molecules have been reported to be involved in lung brosis. Formerly, the expression level of miR-21 was found to increase both in the lung tissue of bleomycin-treated mice and in the lungs of IPF patients [5]. Then, the serum miR-21 was suggested as a representative of miR-21 expression in the lung tissue of IPF patients [15], and additionally, increased serum miR-21 levels were reported in two different IPF studies [7,16]. In our study, the plasma miR-21 levels were signi cantly higher in IPF than in the control. Together with former studies, our results provide further evidence that miR-21 levels are elevated in plasma of the patients with IPF.
To the best of our knowledge, there is no data about the plasma levels of miR-590, miR-192, and miR-215 in IPF. Each one of these miRNAs has been reported to be involved in various brotic diseases but only miR-192 was associated with lung brosis [10,17,18]. MiR-192 expression was found to be increased in the bleomycin-induced brotic lungs of mice and in the sputum of IPF patients [11,12]. Additionally, miR-192 has been shown to be a modulator of airway remodeling in patients with asthma [13]. In this study, the plasma miR-590 levels were signi cantly higher in IPF than in the control, while the expression levels of both miR-192 and miR-215 were similar.
Besides the presence of IPF, our study provided evidence that plasma miRNAs could display expressional alterations with the severity of IPF. The mean plasma level of miR-590 was high in IPF group, but it was decreased as the DLCO values decreased. This data suggests that plasma miR-590 expression increases with IPF development, but along with the disease progression it reduces. Thus, the suppression of miR-590 expression could be related to a negative feedback mechanism associated with the continuing brotic processes. Moreover, plasma level of miR-192 did not change by the presence of IPF, but it was decreased as the radiological severity or the GAP score increased. So, miR-192 could be a promising plasma biomarker for the prognosis of IPF.
In this study, miR-21 was positively correlated with miR-590 in both control and IPF groups. Previously, they were observed to display an inverse expression pattern in ulcerative colitis and there was no correlation between them [19]. Furthermore, our results showed that both miR-21 and miR-590 positively correlated with age in IPF group. The circulating levels of miR-21 were previously reported to increase with age and the miR-590 levels were also found elevated in older subjects [20]. Supporting these data, miR-21 was reported as DNA damage-related circulatory biomarker for aging [21]. Interestingly, we observed that miR-192 and miR-215 were negatively correlated with age in IPF group. Although circulating miR-192 levels were suggested to decrease with age, miR-21 and miR-192 were found elevated in circulating vesicles of aged mice [22]. Since miRNA molecules in the circulation are distributed in several compartments as protein-bound or in exosomes, currently it's unknown whether these different compartments are particularly associated with the speci c diseases [23]. Importantly, the effect of age on miRNA levels seems to be depending on the severity of the current disease and the speci c compartment of miRNAs in which they are distributed.
The interaction of miRNAs with brotic processes could be associated with the brotic signaling pathways. TGFb molecule, closely related to miR-21, is an important factor in pulmonary brosis. In renal brosis, TGFb induces brosis with Smad3 directed upregulation of miR-21, while miR-21 modulates TGFb signaling by reducing the inhibitory Smad7 molecule. Lung injury stimulates miR-21 and TGFb expression and also inhibits Smad7 expression [24]. During bronchial airway remodeling, TGFb induces miR-21 expression but then miR-21 inhibits Smad7 and further stimulates TGFb signaling [25]. Collectively, miR-21 seems to be a positive feedback regulator of TGFb signaling in brosis development.
Together with miR-21, miR-590 has also been implicated in the brotic TGFb signaling. Although TGFb reduces miR-590 expression, miR-590 directly inhibits both TGFb and TGFb receptors to suppress its signaling pathway, but miR-590 also inhibits Smad3 and Smad7 expressions [26][27][28]. Therefore, it has been suggested that miR-590 and TGFb molecules act as negative regulators of each other. However, these data are in contrast with our observation of a higher plasma level of miR-590 in IPF patients than in healthy subjects. A possible explanation for this discrepancy might be associated with the in ammatory response. Pro-in ammatory cytokines regulate miR-590 expression by JAK/STAT pathway [29]. During in ammation processes, STAT3 activates STAT5, and STAT5 is reported to increase miR-590 expression, whereas STAT3 is identi ed as a target of miR-590. In addition, STAT3/5 proteins reported to be involved in the regulation of EMT with TGFb signaling in pulmonary brosis [30]. These data suggest that miR-590 might have a dual role in both in ammation and brosis during IPF progression as a negative feedback regulator.
Interestingly, TGFb-induced miR-192 functions are much more heterogeneous, miR-192 can inhibit or stimulate brosis depending on the cell type. TGFb signaling with Smad3 promotes miR-192 expression, whereas Smad7 reduces miR-192 expression. Previously, miR-192 expression was found reduced in the cigarette smoke-exposed lung tissue. However, during bleomycin-induced pulmonary brosis, miR-192 expression was increased at rst but reduced later [11]. Also, high levels of exosomal miR-192 were found in the sputum samples of IPF patients [12]. Altogether these data support that the effect of TGFb on brosis via miR-192 differs according to the target cell type and miR-192 may play a regulatory role in IPF disease development and progression.
There are limitations in this study. The control group was small in number and the correlation of target miRNAs with age in control group needs to be analyzed with further studies. In addition, it's not possible to know whether miRNAs in the plasma of IPF patients are originated from lung tissues or extrapulmonary tissues, or circulating cells.
In conclusion, the plasma miR-590 and miR-21 levels were found signi cantly higher in the IPF group than in the control group. Moreover, the miR-21 and miR-590 levels were found to be related to age and DLCO, while miR-192 and miR-215 levels were associated with age, GAP score, and honeycombing. Therefore, these miRNAs may take a regulatory role in the development and progression of IPF and may be utilized as a diagnostic or prognostic tool or potentially, as a new therapeutic target. Nevertheless, further research is needed to better understand the roles of plasma miRNAs in IPF.      miR-192 and miR-215 levels according to GAP score subgroups. A, miR-192. The plasma miR-192 levels among the subgroups were signi cantly different with Kruskal-Wallis test (p=0.010). With Dunn`s multiple comparison test, GAP 0-2 subgroup was signi cantly different from other subgroups. B, miR-215. The plasma miR-215 levels among the subgroups were not signi cantly different with Kruskal-Wallis test.

Declarations
There was a signi cant difference between miR-215 levels of GAP 0-2 and 3-4 subgroups with Mann-Whitney U test (p=0.035). Bars represent means and error lines indicate SEM. *p<0.05 Figure 6 miR-192 and miR-215 levels according to UIP pattern on HRCT. A, Plasma miR-192 levels of the patients with UIP pattern were reduced compared to the patients without it (p=0.003). B, Plasma miR-215 levels were similar between the patients with UIP or without UIP pattern (p>0.05). Bars represent means and error lines indicate SEM. *p<0.05

Supplementary Files
This is a list of supplementary les associated with this preprint. Click to download.